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IMMUNOPROTECTIVE RECOMBINANT 
ANTIGEN FROM ANAPLASMA 
MARGINALE, VACCINE COMPOSITIONS 
AND METHODS OF USE 
2 
Ixodes scapularis [8]. See also U.S. Pat. No. 5,869,335, 
incorporated herein by reference. The Virginia isolate of A. 
marginale was initially propagated in the IDES tick cell line 
but subsequently an Oklahoma isolate was propagated in the 
CROSS REFERENCE TO RELATED 
APPLICATION 
5 tick cell line and characterized [9]. Colonies of A. marginale 
in cultured tick cells were morphologically similar to those 
observed in ticks [8-10], and A. marginale harvested from 
cell culture were infective for both cattle and ticks. All 6 
This application claims the benefit of prior filed, copend-
ing U.S. provisional patent application Ser. No. 60/244,333, 10 
filed Oct. 30, 2000, which application is hereby incorporated 
by reference. 
BACKGROUND OF THE INVENTION 
1. Technical Field 15 
MSPs of A. marginale were found to be conserved on the 
cell culture-derived organisms and the antigenic composi-
tion remained the same after successive passage in cell 
culture. The A. marginale isolate antigenic identity, as 
determined by the molecular weight of the MSPla, was 
retained in culture [9, 11]. 
MSPl complex isolated A. marginale also has been 
utilized for the vaccination of ruminants, as disclosed by 
McGuire et al. in U.S. Pat. No. 5,549,898 issued Aug. 27, 
1996 (said patent being incorporated herein by reference). 
The present invention relates to antigenic polypeptides 
and proteins, related vaccines and methods useful to induce 
an immune response which is protective to reduce the 
severity or prevent infection by ehrlichial parasites of the 
species Anaplasma marginale. 
2. Background 
Existing vaccines, however, including formulations using 
20 partially purified parasites from infected erythrocytes and 
cultured tick cells, are currently handicapped by mecha-
nisms developed by the parasite to hide the most relevant 
epitopes from the host immune system. The inclusion of 
recombinant protein preparations in vaccine formulations 
25 would allow the development of host immune response 
against relevant epitopes not available for the host immune 
system in natural conformations present in whole-parasite or 
parasite-derived purified antigens. 
Anaplasmosis is a tick-borne disease of cattle caused by 
the obligate intraerythrocytic ehrlichial pathogen A. margi-
nale. The acute phase of the disease is characterized by 
severe anemia, weight loss, fever, abortion, lower milk 
production and often death. The only known site of devel-
opment of A. marginale in cattle is within bovine erythro-
cytes. The number of infected erythrocytes increases loga-
rithmically and removal of these infected cells by 30 
phagocytosis results in development of anemia and icterus 
without hemoglobinemia and hemogloinuria. Biological 
transmission of A. marginale is effected by feeding ticks, 
while mechanical transmission occurs when infected blood 
is transferred to susceptible animals by biting flies or by 35 
blood-contaminated fomites. Cattle that recover from acute 
SUMMARY OF THE INVENTION 
Experimental results described by the inventors in 
copending U.S. provisional patent application Ser. No. 
60/244,333 demonstrate a differential role for MSPla and 
MSPlb polypeptides of the MSPl surface protein complex 
for adherence of A. marginale to bovine erythrocytes and 
tick cells. Recombinant MSPla expressed in E. coli was 
shown to be an adhesin for bovine erythrocytes and both 
native and cultured tick cells. In contrast, recombinant E. 
infection remain persistently infected and serve as reservoirs 
for mechanical transmission and infection of ticks. Approxi-
mately 20 species of ticks have been incriminated as vectors 
worldwide. The developmental cycle of A. marginale in 
ticks is complex and coordinated with the tick feeding cycle. 
After infection and development of A. marginale in tick gut 
cells, many other tick tissues become infected, including the 
salivary glands from where the ehrlichia is transmitted to 
vertebrates during feeding. 
40 coli expressing MSPlb adhered only to bovine erythrocytes 
and not to tick cells. The role of the MSPl complex, 
therefore, was determined to vary among vertebrate and 
invertebrate hosts. 
The present invention is based upon the surprising dis-
MSPl is one of six major surface proteins (MSPs) that 
have been described on A. marginale from bovine erythro-
cytes and has been found to be conserved on tick salivary 
gland-derived A. marginale [1]. MSPl is a heterodimer 
composed of two structurally unrelated polypeptides: 
45 covery that cattle immunized with the recombinant MSPla 
surface protein antigen of the MSPl complex alone or in 
combination with tick cell culture-derived A. marginale are 
better protected against A. marginale infection as demon-
strated by a lower reduction in packed cell volume (PCV) 
50 and lower peak parasitemia (PPE) than cattle immunized 
with the MSPl complex, a combination of uncomplexed 
MSPla and MSPlb surface protein antigens, the MSPlb 
antigen alone, cell culture derived A. marginale, or cell 
culture derived A. marginale combined with MSPlb. 
MSPla which is encoded by a single gene, mspla, and 
MSPlb which is encoded by at least two genes, mspl~l and 
msp1~2 [2, 3]. MSPla is variable in molecular weight 
among geographic isolates because of a variable number of 
tandem 28 or 29 amino acid repeats in the amino terminal of 
the protein. Immunization of cattle with affinity-purified 
native MSPl complex has previously been shown to induce 
protective immunity in cattle that received homologous or 
heterologous challenge with A. marginale geographic iso-
lates [ 4, 5]. In addition, MSPla and MSPlb expressed by 60 
recombinant Escherichia coli were shown to be putative 
adhesins to bovine erythrocytes [6, 7]. Although the MSPl 
complex has been suggested to be involved in erythrocyte 
invasion, its role in infection and multiplication of the 
parasite in the tick vector has not been reported. 
Recently, A. marginale has been grown in continuous 
culture in a cell line, IDES, derived from embryos of the tick 
55 Indeed, only erythrocyte-derived A. marginale appears to 
confer like protection. 
65 
Thus, in one embodiment of the present invention there is 
provided a vaccine composition for inducing an immune 
response in a ruminant, the vaccine composition comprising 
the recombinant MSPla purified surface protein antigen of 
A. marginale or subunits thereof, alone or in combination 
with other antigenic components, wherein the vaccine com-
position further comprises a pharmaceutically acceptable 
carrier or diluent. 
In another embodiment of the present invention there is 
provided, a method for inducing an immune response in a 
ruminant to provide immune protection which reduces the 
US 6,939,549 B2 
3 
severity of or prevents infection by A. marginale, the method 
comprising administering to said ruminant an effective 
amount of the inventive vaccine composition. 
4 
between and within populations of A. marginale from dif-
ferent geographical regions and life cycle stages but con-
serve a high degree of similarity. Sequence diversity is 
A better understanding of the present invention, its several 
aspects, and its advantages will become apparent to those 5 
skilled in the art from the following detailed description, 
taken in conjunction with the attached figures, wherein there 
mainly due to point mutations in variable regions, perhaps 
due to selective immune pressure. The genetic structure of 
mspl a and ~ genes together with the vital function of 
codified polypeptides permits the inclusion of recombinant 
MSPl polypeptides, or its functional domains, in vaccine 
formulations against A. marginale. 
is described the preferred embodiment of the invention, 
simply by way of illustration of the best mode contemplated 
for carrying out the invention. 10 The experiments described and examples provided here-
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a graphical illustration of the immune response 
against MSPla and MSPlb determined by Western blot 
analysis of sera derived from immunized cattle and controls 
generated in connection with the experimental results 
reported herein. 
FIG. 2 is a graphical illustration of the reduction in PCV 
achieved by various combinations of antigens and controls 
in connection with the experimental results reported herein. 
DETAILED DESCRIPTION OF THE 
INVENTION 
inafter demonstrate that cattle immunized with recombinant 
MSPla alone or in combination with tick cell culture 
derived A. marginale are unexpectedly better protected 
against A. marginale infection as demonstrated by a lower 
15 reduction in packed cell volume (PCV) and lower peak 
parasitemia (PPE) than cattle immunized with the MSPl 
complex, a combination of uncomplexed MSPla and 
MSPlb surface protein antigens, the MSPlb antigen alone, 
cell culture derived A. marginale, or cell culture derived A. 
20 marginale combined with MSPlb. Indeed, only erythrocyte-
derived A. marginale appears to confer like protection. 
EXAMPLE 1 
Before explaining the present invention in detail, it is 25 
important to understand that the invention is not limited in 
Preparation of Recombinant E. coli Expressing 
MSPl a and Preparation of Antigen 
The mspl a gene was cloned by PCR from the Oklahoma 
isolate of A. marginale derived from infected erythrocytes. 
DNA was extracted from 1 ml stored blood samples con-
taining infected bovine erythrocytes collected during high 
parasitemia employing 250 µL Tri Reagent (Sigma) and 
following manufacturer's recommendations. Extracted 
its application to the details of the embodiments and steps 
described herein. The invention is capable of other embodi-
ments and of being practiced or carried out in a variety of 
ways. It is to be understood that the phraseology and 30 
terminology employed herein is for the purpose of descrip-
tion and not of limitation. DNA was resuspended in 100 µL water. The mspla gene 
was amplified from 1 µL DNA by PCR using 10 pmol of In accordance with the present invention there is provided 
a new vaccine against the ehrlichial cattle pathogen A. 
marginale through the use of discrete recombinant MSPla 
and polypeptides derived from MSPla containing the immu-
noprotective and functional regions that are expressed in E. 
coli. In one aspect, only recombinant MSPla or immuno-
protective and functional regions thereof are utilized as the 
antigenic component of the vaccine. In another aspect, 
recombinant MSPla or subunits thereof are utilized in 
combination with other antigen preparations, particularly 
antigen preparations derived from A. marginale-infected 
cultured tick IDES cells. 
MSPla and MSPlb are isolated from A. marginale initial 
bodies as a complex of two noncovalently linked, antigeni-
cally distinct polypeptides. It is possible that the association 
between MSPla and MSPlb in the surface protein complex 
allows the parasite to more effectively bind to erythrocyte 
and/or tick cell components. MSPla could be the essential 
subunit in the recognition of the tick cell receptor, while the 
binding to the erythrocyte receptor could be mediated pri-
marily by MSPlb or by both protein subunits through the 
binding of distinct erythrocyte components. Additionally, 
the association between MSPla and MSPlb could stabilize 
and/or properly conform the MS Pl complex [ 6]. 
MSPla is encoded by a single monocystronic gene, 
mspla, which is polymorphic among geographical isolates 
of A. marginale [12, 13, 15]. A. marginale isolates differ in 
the number of 28-29 amino acids tandem repeats within the 
MSPla polypeptide [13, 15], which contain a neutralization-
sensitive epitope [ 4, 13]. However, the sequence of mspla 
does not change during the multiplication of the parasite in 
the bovine host and the tick vector. The second MSPl 
subunit, MSPlb, is encoded by at least two monocystronic 
genes, mspl~l and msp1~2 [3]. These loci are polymorphic 
35 each primer MSPlaP: 5'GCATTACAACGCAACGCT-
TGAG3' (SEQ. ID NO: 1) and MSP1a3: 5'GCTTTACGC-
CGCCGCCTGCGCC3' (SEQ. ID NO: 2) in a 50-µL volume 
PCR employing the Access RT-PCR system (Promega). 
Reactions were performed in an automated DNA thermal 
40 cycler (Eppendort) for 35 cycles. After an initial denatur-
ation step of 30 sec at 94° C., each cycle consisted of a 
denaturing step of 30 sec at 94° C. and an annealing-
extension step of 2.5 mm at 68° C. The program ended by 
storing the reactions at 40° C. PCR products were electro-
45 phoresed on 1 % agarose gels to check the size of amplified 
fragments. The amplified fragments were resin purified from 
PCR reactions (Wizard Promega) and cloned into pGEM-T 
vector (Promega) for sequencing both strands (Core 
Sequencing Facility, Department of Biochemistry and 
50 Molecular Biology, Noble Research Center, Oklahoma State 
University). 
For high level expression of MSPla, mspla coding 
region was amplified from perl (mspla in pGEM-T vector) 
plasmid DNA by PCR using the primers 5'CCGCTC-
55 GAGATGTAGCGGAGTATGTGTCC3' (SEQ. ID NO: 3) 
and 5'GAAGATCTCGCCGCCGCCTGCGCC3' (SEO. ID 
NO: 4). The mspla amplification product was digested with 
XhoI and Bglll and inserted into the cloning site of pFLAG-
CTC expression vector (Sigma). Recombinant plasmid was 
60 named pFLCl a. In this construct, the inserted gene is under 
the control of the inducible tac promoter and yield full-
length MSPla polypeptide, with a C-terminal fusion of a 
FLAG marker octapeptide. The fidelity and orientation of 
the construct was verified by sequencing. For expression of 
65 MSPla recombinant polypeptides, pFLCla expression plas-
mid was transformed into E. coli K-12 (strain JM109). 
Transformed E. coli strains were inoculated in LB contain-
US 6,939,549 B2 
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ing 50 µg/ml Ampicillin and 0.4% glucose. Cultures were 
grown at 37° C. to OD600 nm=0.4. IPTG was then added to 
0.5 mM final concentration, and incubation continued dur-
ing 4 h, for induction MSPla expression. Cells were col-
lected by centrifugation and membranes extracted after 
sonication and centrifugation. MSPlb was cloned, 
expressed and purified in a similar way. Doses of 5 ml 
containing 100 µg recombinant antigens were used for 
vaccination in subsequent studies. 
EXAMPLE 2 
Analysis of the Protective Capacity of Vaccine 
Preparations Containing Recombinant MSPla 
1. Propagation of Anaplasma marginale in tick cell cul-
ture and preparation of immunogen. The IDES (ATCC CRL 
11973) tick cell line derived from embryos oflxodes scapu-
laris was maintained at 31 ° C. in L-15B medium, pH 7.2, 
supplemented with 5% heat inactivated fetal bovine serum 
(FBS; Sigma, USA), 10% tryptose phosphate broth (Difeo, 
USA) and 0.1 % bovine lipoprotein concentrate (ICN, USA). 
Cultures were grown in 25-cm2 plastic flasks (Nunc, 
Rosekilde, Denmark) with 5 ml of medium, and the medium 
was replaced weekly. The cells were subcultured at 1:5 to 
1:20, and the cells became tightly adherent to the culture 
substrate and multiplied with a population doubling time of 
3 to 5 days to a density of about 5xl06 cells/ml. Nearly 
confluent monolayers from each passage were collected and 
stored in liquid nitrogen in medium with 10% DMSO. 
6 
4. Immunizations. All cattle were immunized 3 times by 
subcutaneous injection of the antigen at weeks 1, 4 and 6. 
Each antigen dose was 5 ml in volume and contained an 
antigen in the adjuvant, XTEND® III (Grand Laboratories, 
5 Larchwood, Iowa). All cattle were challenge-exposed 10 
weeks after the last immunization with lx107 A. marginale 
infected erythrocytes collected from a calf experimentally 
infected with the Oklahoma isolate of A. marginale. Blood 
of the immunized and control cattle was monitored for 
10 infection with A. marginale by microscopic examination of 
blood smears and hematology was done daily after the onset 
of infection. Parameters evaluated in cattle included deter-
mination of the peak percent infected erythrocytes (PPE), 
percent reduction in the packed cell volume (PCV), and the 
15 prepatent period (days) determined from the day of 
challenge-exposure to the onset of infection. 
5. Collection of blood and serum samples. Whole blood 
was collected in vacutainer tubes containing EDTA and used 
for preparation of stained blood smears for light microscopy 
20 and for determination of the PCV. Serum samples were 
collected from each animal before immunization, weekly 
until the cattle were challenge-exposed and daily after cattle 
developed parasitemia as a result of challenge-exposure. 
Serum samples were stored at - 70° C. until tested by 
25 competitive ELISA and Western blots. 
Tick cell cultures infected with the Oklahoma isolate of A. 30 
6. Characterization of the immune response in vaccinated 
cattle by competitive ELISA and Western blots. Antibody 
responses of all immunized and control cattle at two weeks 
after the last immunization to MSPla, MSPlb and MSP5 
were determined using ELISAs specific for detection of 
antibodies to each of these MSPs. Antibody responses of all marginale were propagated. Terminal cell cultures were 
harvested, the cells centrifuged, and the contents of each T25 
flask was resuspended in 1 ml PBS and stored at - 70° C. 
until used as antigen for immunogen doses. The antigen 
aliquots were thawed, pooled and a sample was taken and 
tested by indirect ELISA The cell culture-derived antigen 
was inactivated with beta propiolactone (BPL) and the 
volume was adjusted to 5 ml so that each dose contained 
approximately 2xl010 A. marginale. 
2. Preparation of A. marginale antigen from bovine eryth-
rocytes. Two susceptible, splenectomized calves (PA432 and 
PA433) were each inoculated with 2.5 ml blood stabilate 
immunized and control cattle at two weeks after the last 
immunization to MSPla and MSPlb were also analyzed by 
Western blot. One hundred micrograms of recombinant 
35 MSPla or MSPlb were loaded in an 8% polyacrylamide gel. 
SDS-PAGE gels were transferred to a nitrocellulose mem-
brane. The membrane was blocked with 5% skim milk for 1 
hr at room temperature. Sera from immunized cattle was 
diluted 1:200 in TBS. Serum from an uninfected bovine was 
40 included as a negative control. All sera were incubated with 
the membrane for 1 hr at room temperature using a Mini-
Protean II Multi-screen (BioRad, USA). The membrane was 
washed 3 times with TEST and incubated for 1 hr at room ( 40% parasitemia) collected from a calf with the Virginia 
isolate of A. marginale. The calves were monitored for 
infection by examination of stained blood smears. Blood 45 
was collected from PA432 at parasitemias of 13.6% and 
32.7% and from PA433 at parasitemias of 12.2% and 12.9%. 
After each collection, the erythrocytes were washed 3 times 
temperature with goat anti-rabbit IgG alkaline phosphatase 
conjugate (KPL, USA) diluted 1:10,000. The membrane was 
washed again and the color developed using Sigma Fast 
BCIP/NBT alkaline phosphatase substrate tablets. The 
membrane was then examined for recognition of the bands 
corresponding to MSPla and MSPlb. in PBS, each time removing the buffy coat. The erythrocytes 
were frozen at - 70° C. 1:1 in RPMI cell culture medium 50 7. Statistical analysis. For the analysis of results from the 
until used as antigen for the immunization studies. The 
frozen erythrocyte antigen was thawed, washed in PBS, and 
centrifuged. The resulting pellet was washed to remove the 
hemoglobin, after which the antigen was pooled and inac-
tivated with BPL. An aliquot was tested by ELISA as 
described previously for the erythrocyte antigen preparation 
using a known erythrocyte standard. Doses (5 ml) were 
prepared that contained approximately 2xl010 A. marginale. 
3. Experimental design. Fifty, 16-month month old Angus 
cattle were randomly assigned into ten groups of five cattle 
each that were immunized with various antigens as follows. 
(1) MSPl complex, (2) MSPla and MSPlb, (3) MSPla, (4) 
MSPlb, (5) cell culture-derived A. marginale, (6) cell 
culture-derived A. marginale and MSPla, (7) cell culture-
derivedA. marginale and MSPlb, (8) erythrocyte-derivedA. 
marginale, (9) uninfected IDES tick cells and (10) adjuvant 
only. 
immunization experiment, pairwise comparisons (Student's 
t test) were conducted to compare results between cattle 
immunized with antigen preparations and the controls. 
Parameters analyzed included the prepatent period (days), 
55 the peak percent parasitized erythrocytes (PPE) and the 
percent reduction in the packed cell volume (PCV). Mean 
antibody levels were compared using an ANOVA test. 
8. Results. Antibody titers against MSPla, MSPlb and 
MSP5 in immunized cattle peaked two weeks after the last 
60 immunization. The immune response against MSPla, 
MSPlb and MSP5 was analyzed by Western blot. Cattle 
immunized with recombinant antigen preparations 
responded to recombinant proteins included on each prepa-
ration (FIG. 1). Cattle immunized with tick cell derived A. 
65 marginale antigens and with infected erythrocytes-derived 
antigens recognized primarily MSPlb or MSPla, respec-
tively (FIG. 1). 
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Protection was evaluated using the reduction in PCV, the 
PPE and the prepatent period. No differences were observed 
in the prepatent period. The PPE was reduced in cattle 
immunized with MSPla, MSPlb, the combination of 
recombinant antigens with infected tick cells-derived anti-
gens and in animals immunized with infected erythrocytes-
derived antigens as shown in Table 1. 
TABLE 1 
Peak Parasitemia (%) 
Group Ave SD p 
MSPl 5.5 2.8 0.13 
la+ lb 6.0 1.6 0.14 
la 4.8 0.6 0.03 
lb 3.9 1.0 0.01 
TC 4.1 2.3 0.03 
la+ TC 4.7 1.4 0.03 
lb+ TC 3.9 0.8 0.01 
REC 2.7 1.1 0.004 
Saline 5.5 1.4 0.08 
Cells 7.4 2.3 
The reduction in PCV, associated with clinical signs, was 
significantly reduced in cattle immunized with MSPla com-
bined with infected tick cell-derived antigens and in cattle 
immunized with erythrocyte-derived antigens (See FIG. 2, 
wherein Reduction PCV=[(Ave Start PCV-Lowest PCV)/ 
Start PCV]xlO0). 
The results of these experiments demonstrated that: 
a. Cattle immunized with infected tick cell-derived anti-
gens had a preferential recognition for MSPlb while 
cattle immunized with erythrocyte-derived antigens 
showed a bias toward MSPla. The bias in the antibody 
response against MSPla or MSPlb in cattle immunized 
with A. marginale antigens from IDES tick cells or 
bovine erythrocytes suggests that the MSPl complex 
exposure on the surface of parasites may vary during 
multiplication on the tick and mammalian hosts; 
b. The immunization with the MSPl complex or with 
MSPla and MSPlb together did not protect cattle after 
challenge with A. marginale despite that cattle 
responded to both antigens; and 
c. Cattle with a predominant immune response against 
MSPla (groups immunized with MSPla, MSPla plus 
infected tick cell-derived antigens and infected 
erythrocyte-derived antigens) were protected againstA. 
marginale infection as demonstrated by the lower 
reduction in PCV. 
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isolate mspla clone penl [14]) mutant lacking the tandem 
repeats was constructed by PCR. Oligonucleotide primers 
RI0R (5'-CCGAATTCCATGTTAGCGGCTAATTGGCGG-
CAAGAGATGCG-3') (SEQ. ID NO: 5) and MSP1a3BII 
5 (5'-CCAGATCTCTTTACGCCGCCGCCTGCGCC-3') 
(SEQ. ID NO: 6) were designed to amplify the mspla gene 
lacking 6 amino acids preceding the repeats and the tandem 
repeats in a 50 µl volume PCR (0.2 µMeach primer, 1.5 mM 
MgSO4 , 0.2 mM dNTP, lXAMV/Tfl reaction buffer, 5 u Tfl 10 DNA polymerase) employing the Access RT-PCR system 
(Promega, USA). Reactions were performed in an auto-
mated DNA thermal cycler (Eppendorf MASTERCY-
CLER® personal, USA) for 35 cycles. After an initial 
15 denaturation step of 30 sec at 94 ° C., each cycle consisted of 
a denaturing step of 30 sec at 94° C. and an annealing-
extension step of 2.5 min at 68° C. The program ended by 
storing the reactions at 4° C. The primers introduced anATG 
initiation codon and Eco RI and BgI II restriction sites for 
20 cloning into the pFLAG-CTC expression vector (Sigma). 
The resulting plasmid pAF0Rl was transformed into E. coli 
JM109 and induced for expression of mutant MSPla as 
previously reported for MSPla [14]. For the expression of 
MSPla (Oklahoma isolate mspl a clone perl [14]) tandem 
25 repeats in E. coli, this region was amplified using oligo-
n u cl e o tide primers RNOKBS5 (5'-
GAGATCTGCTGATGGCTCGTCAGCGGG-3') (SEQ. ID 
NO: 7) and RNOKBS3 (5'-GGTCGACCCT-
GATTGAGACGATGTACTGGCC-3') (SEQ. ID NO: 8). 
30 The PCR was conducted as previously described but with 
amplification cycles consisting of a denaturing step of 30 sec 
at 94° C., an annealing step of 30 sec at 58° C. and an 
extension step of 1 mm at 68° C. The 5' and 3' amplification 
primers contained Bgl II and Sal I restriction sites, 
35 respectively, for cloning into pFLClb [14] for expression in 
E. coil as a fusion peptide to the COOR-terminus of MSPlb 
(locus ~1, Oklahoma isolate). The resulting plasmid 
pFlbRNO4 was transformed into E. coli JM109 and induced 
for expression of mutant MSPlb>MSPla-repeats protein as 
40 previously reported for MSPlb [14]. All constructs were 
sequenced at the Core Sequencing Facility, Department of 
Biochemistry and Molecular Biology, Noble Research 
Center, Oklahoma State University using ABI Prism dye 
terminator cycle sequencing protocols developed by Applied 
45 Biosystems (Perkin-Elmer Corp., Foster City, Calif.). 
Expression of recombinant mutant proteins was assayed 
by SDS-PAGE, Western blot or live-cell immunofluores-
cence assay as previously reported [14]. The hemagglutina-
50 tion of bovine erythrocytes and adhesion to cultured IDES 
tick cells of recombinant E. coli expressing the wild type and 
mutant proteins was evaluated in a microtitre hemaggluti-
nation and E. coli recovery adhesion assays, respectively, as 
reported [ 14]. 
It can thus be appreciated that the utilization of recom-
binant MSPla in vaccines provides an advantageous mecha-
nism to achieve resistance in cattle against A. marginale 
infection. Whereas erythrocyte-derived A. marginale is dis-
advantaged due to cost, difficulties in purifying antigen from 
bovine membranes, problems with preventing pathogen 55 
contamination and difficulties in standardization, recombi-
nant MSPla may be readily and cost effectively prepared in 
2. Results. To study the function and structural organiza-
tion of tandem repeated peptides in MSPla we selected a 
recent A. marginale field isolate from Oklahoma that is 
tick-transmissible and for which we have cloned and char-
acterized MSPla and MSPlb. A recombinant mutant MSPla 
a standardized, pure form free of bovine erythrocyte mem-
branes and antigens that might result in formation of an 
immune response to bovine blood cells. 
EXAMPLE 3 
Function of MSPla Tandem Repeats in Adhesion 
to Host Cell Receptors 
1. Construction, expression in E. coli and characterization 
of wild type MSPla and mutants. A MSPla (Oklahoma 
60 was constructed lacking the tandem repeated peptides and 
expressed in E. coli. The recombinant mutant protein was 
expressed at high levels and was secreted to the E. coli 
membrane as shown by live-cell immunofluorescence. 
Nevertheless, the adhesion to cultured IDES tick cells of 
65 recombinant E. coli expressing the mutant protein was 
abolished when compared to the wild type MSPla (Table 2). 
To demonstrate that the MSPla repeats were not only 
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necessary but sufficient to confer adhesion of recombinant E. 
coli to tick cells, we then constructed a chimeric protein 
containing the MSPla tandem repeated peptides fused to the 
COOR-terminus of the MSPlb. MSPlb did not confer an 
adhesive phenotype when expressed in E. coli (Table 3). 
However, E. coli expressing the chimeric protein adhered to 
cultured IDES tick cells at levels comparable to the wild type 
MSPla-expressing E. coli (Table 3). 
The capacity of MSPla to hemagglutinate bovine eryth-
rocytes was also mediated by the tandem repeats. Recom-
binant E. coli expressing the MSPla lacking the tandem 
repeats were unable to hemagglutinate bovine erythrocytes 
(Table 2) while the chimeric MSPlb>MSPla-repeats protein 
expressed in E. coli conferred to recombinant bacteria a 
higher hemagglutination capacity (Table 3) when compared 
to wild type MSPs. 
TABLE 2 
Hemagglutination of bovine erythrocytes and adhesion to cultured 
tick IDES cells by recombinant E. coli expressing A. marginale 
(Oklahoma isolate) MSPla wild type and mutant protein without repeats 
Plasmid carried by recombinant E. coli 
pFLCla 
Relevant protein expressed MSPla 
No. of CFU (mean ± SD) 500 ± 141 
recovered from IDES cells 
(N- 3) 
Average fold increase over 2 
p33 control 
P (Student's t-Test) 0.05 
Average fold decrease over 
MSPla (OK) 
P (Student's t-Test) 
Hemagglutination of 
bovine erythrocytes 
(N- 3)' 
ao, no hemagglutination; 
1, weak hemagglutination; 
2, moderate hemagglutination; 
3, near maximum hemagglutination; 
4, maximum hemagglutination [7]. 
pAF0Rl 
MSPla-no 
repeats 
mutant 
14 ± 18 
36 
0.02 
0 
TABLE 3 
No 
p33 plasmid 
None None 
231 ± 129 0 
0 0 
Hemagglutination of bovine erythrocytes and adhesion to cultured 
IDES tick cells of E. coli expressing wild type MSPla or MSPlb 
(Oklahoma isolate) and MSPlb > MSPla-repeats mutant proteins 
Plasmid carried by recombinant E. coli 
pFLCla pFLC1b2 pF1bRNO4 
Relevant protein expressed MSPla MSPlb MSPlb > MSPla-
repeats 
No. of CFU recovered from 975 ± 742 18 ± 17 530 ± 325 
IDES cells (Ave ± SD) 
(N- 2) 
Average fold increase over 54 29 
pFLC1b2 (MSPlb) 
Hemagglutination of bovine 4 5 
erythrocytes (N - 2)' 
aPlates were incubated for 2 hours at 4 ° C. and results scored essentially 
as reported by McGarey and Allred [7]: 
0, no hemagglutination; 
1, weak hemagglutination; 
2, moderate hemagglutination; 
3, near maximum hemagglutination; 
4, maximum hemagglutination; 
5, maximum hemagglutination in 1 hour. 
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Accordingly, it can be appreciated that subunits derived 
from MSPla are useful as well in the inventive vaccine 
compositions. The inclusion of MSPla region(s) effecting 
MSPla biological function could enhance the host immune 
5 response directed against relevant immunoprotective 
epitopes. 
The preparation of vaccines utilizing as distinct antigenic 
components MSPla is easily accomplished using well 
known methods and techniques. The vaccine and/or antigen 
10 preparation is combined into a formulation in an amount 
effective to provide for a protective immune response 
against infection with A. marginale. A protective immune 
response againstA. marginale decreases the clinical signs of 
anaplasmosis. Clinical symptoms of anaplasmosis include a 
reduction in packed red cell volume of about 25 to 80% and 
15 parasitemia of the red blood cells of about 15 to 70%. A 
decrease in the symptoms of anaplasmosis includes preven-
tion of the reduction in the packed red cell volume and a 
decrease in percent parasitemia. Preferably, a protective 
response includes packed red cell volume change of 25% or 
20 less compared with control animals and/or a decrease in 
parasitemia to about 5 to 25% of the red blood cells or less 
depending on the conditions. Measurements of packed red 
cell volume and percent parasitemia are conducted using 
standard methods. Vaccine preparations are combined with 
physiologically acceptable carriers to form vaccines. The 
preferred physiologically acceptable carrier is an oil-based 
adjuvant. 
25 
30 
35 
Preferably, the inventive vaccine formulation is set to 
contain about 100 micrograms of recombinant antigens 
associated to E. coil membranes in an oil-based adjuvant 
such as XTEND® III (Grand Laboratories, Larchwood, 
Iowa). 
The vaccines may be administered by a variety of routes 
including intravenously, intraperitoneally, intramuscularly, 
and subcutaneously. The preferred route of administration is 
subcutaneous. The vaccine can be administered in a single 
dose or multiple doses until a protective effect is achieved. 
While the invention has been described with a certain 
degree of particularity, it is understood that the invention is 
not limited to the embodiment(s) set for herein for purposes 
40 of exemplification, but is to be limited only by the scope of 
the attached claim or claims, including the full range of 
equivalency to which each element thereof is entitled. 
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<160> NUMBER OF SEQ ID NOS: 8 
<210> SEQ ID NO 1 
<211> LENGTH: 22 
<212> TYPE: DNA 
<213> ORGANISM: artificial 
<220> FEATURE: 
SEQUENCE LISTING 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 1 
gcattacaac gcaacgcttg ag 
<210> SEQ ID NO 2 
<211> LENGTH: 22 
<212> TYPE: DNA 
<213> ORGANISM: artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 2 
gctttacgcc gccgcctgcg cc 
<210> SEQ ID NO 3 
<211> LENGTH: 30 
<212> TYPE: DNA 
<213> ORGANISM: artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide sequence 
<400> SEQUENCE: 3 
ccgctcgaga tgttagcgga gtatgtgtcc 
<210> SEQ ID NO 4 
<211> LENGTH: 24 
<212> TYPE: DNA 
<213> ORGANISM: artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 4 
[14] de la Fuente, J., Garcia-Garcia, J. C., Blouin, E. F., 
Kocan, K. M. Differential adhesion of major surface 
proteins la and lb of the ehrlichial cattle pathogen 
Anaplasma marginale to bovine erythrocytes and tick 
cells. Int. J. Parasitol. 2001; 31: 145-153. 
[15] de la Fuente, J., van den Bussche, R. A., Kocan, K. M. 
Molecular phylogeny and biogeography of North Ameri-
can isolates of Anaplasma marginale. Veterinary Parasi-
tology 2001; 97: 65-76. 
22 
22 
30 
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-continued 
gaagatctcg ccgccgcctg cgcc 
<210> SEQ ID NO 5 
<211> LENGTH: 41 
<212> TYPE: DNA 
<213> ORGANISM: artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 5 
ccgaattcca tgttagcggc taattggcgg caagagatgc g 
<210> SEQ ID NO 6 
<211> LENGTH: 29 
<212> TYPE: DNA 
<213> ORGANISM: artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 6 
ccagatctct ttacgccgcc gcctgcgcc 
<210> SEQ ID NO 7 
<211> LENGTH: 27 
<212> TYPE: DNA 
<213> ORGANISM: artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 7 
gagatctgct gatggctcgt cagcggg 
<210> SEQ ID NO 8 
<211> LENGTH: 31 
<212> TYPE: DNA 
<213> ORGANISM: artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: oligonucleotide primer 
<400> SEQUENCE: 8 
ggtcgaccct gattgagacg atgtactggc c 
What is claimed is: 45 
24 
41 
29 
27 
31 
8. The method according to claim 6, wherein said immu-
nogen of said vaccine composition is tick cell culture 
derived A. marginale. 
1. A vaccine composition for inducing an immune 
response in a ruminant, said vaccine composition compris-
ing recombinant MSPla in combination with an immunogen 
derived from A. marginale, wherein said immunogen is not 
isolated or recombinant MSPlb and said vaccine composi-
tion further comprises a pharmaceutically acceptable carrier 
or diluent. 
2. The vaccine according to claim 1, wherein said immu-
nogen is tick cell culture derived A. marginale. 
9. The method according to claim 8, wherein said tick cell 
50 culture comprises Ixodes scapularis tick cell line IDES. 
10. The method according to claim 6, wherein said 
recombinant MSPla of said vaccine composition is from the 
Oklahoma isolate of A. marginale. 
3. The vaccine according to claim 2, wherein said tick cell 55 
culture comprises Ixodes scapularis tick cell line IDES. 
4. The vaccine according to claim 1, wherein said recom-
binant MSPla is from the Oklahoma isolate of A. marginale. 
5. The vaccine according to claim 4, wherein said immu-
nogen is derived from the Oklahoma isolate of A. marginale. 60 
6. A method for inducing a protective immune response in 
a ruminate againstA. marginale comprising administering to 
the ruminant an effective dose of the vaccine composition of 
claim 1. 
7. The method according to claim 6, wherein said dose 65 
comprises approximately 100 µg of said recombinant 
MSPla. 
11. The method according to claim 10, wherein said 
immunogen of said vaccine composition is derived from the 
Oklahoma isolate of A. marginale. 
12. The method according to claim 8, wherein said dose 
comprises approximately 2xl010 of said tick cell culture 
derived A. marginale. 
13. The vaccine composition according to claim 1, 
wherein said recombinant MSPla is associated to E. coli 
membrane fractions. 
* * * * * 
